Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
424.199822016
InChI
InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
InChI Key
InChIKey=XPCFTKFZXHTYIP-PMACEKPBSA-N
IUPAC Name
2-[(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid
Traditional IUPAC Name
benazepril
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O
pKa (strongest acidic)
3.53
pKa (Strongest Basic)
5.36
Refractivity
115.23 m3·mol-1
Dược Lực Học :
Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by estarases to its active Benazeprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.
Cơ Chế Tác Dụng :
Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Benazeprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.
Dược Động Học :
▧ Absorption :
Peak in plasma within 0.5-1.0 hours. The extent of absorption is at least 37% as determined by urinary recovery and is not significantly influenced by the presence of food in the GI tract.
▧ Protein binding :
benazepril, 97%; benazeprilat, 95%
▧ Metabolism :
Cleavage of the ester group (primarily in the liver) converts benazepril to its active metabolite, benazeprilat. Benazepril and benazeprilat may be conjugated to glucuronic acid prior to urinary excretion.
▧ Route of Elimination :
Benazepril and benazeprilat are cleared predominantly by renal excretion in healthy subjects with normal renal function. Nonrenal (i.e., biliary) excretion accounts for approximately 11%-12% of benazeprilat excretion in healthy subjects.
▧ Half Life :
10-11 hours
▧ Clearance :
* 0.35 L/hr/kg [pediatric hypertensive patients receiving multiple daily doses of Benazepril hydrochloride 0.1 - 0.5 mg/kg]
* 0.13 L/hr/kg [healthy adults receiving a single dose of 10 mg]
Độc Tính :
Most likely symptom of overdosage is severe hypotension. Most common adverse effects include headache, dizziness, fatigue, somnolence, postural dizziness, nausea, and cough.
Chỉ Định :
For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.
Tương Tác Thuốc :
-
Amiloride
Increased risk of hyperkalemia
-
Azilsartan medoxomil
Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.
-
Drospirenone
Increased risk of hyperkalemia
-
Icatibant
Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely.
-
Lithium
The ACE inhibitor increases serum levels of lithium
-
Potassium
Increased risk of hyperkalemia
-
Spironolactone
Increased risk of hyperkalemia
-
Tizanidine
Tizanidine increases the risk of hypotension with the ACE inhibitor
-
Tobramycin
Increased risk of nephrotoxicity
-
Treprostinil
Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
-
Triamterene
Increased risk of hyperkalemia
Liều Lượng & Cách Dùng :
Tablet, film coated - Oral - 10 mg
Tablet, film coated - Oral - 20 mg
Tablet, film coated - Oral - 40 mg
Tablet, film coated - Oral - 5 mg
Dữ Kiện Thương Mại
Giá thị trường
-
Giá bán buôn : USD >1.07
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.07
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.07
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.07
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.14
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.31
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.9
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.9
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.9
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.9
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.94
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.95
Đơn vị tính : tablet
-
Giá bán buôn : USD >1.97
Đơn vị tính : tablet
-
Giá bán buôn : USD >2.0
Đơn vị tính : tablet
-
Giá bán buôn : USD >2.0
Đơn vị tính : tablet
-
Giá bán buôn : USD >2.0
Đơn vị tính : tablet
-
Giá bán buôn : USD >2.08
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.58
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.69
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.79
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.84
Đơn vị tính : tablet
-
Giá bán buôn : USD >0.99
Đơn vị tính : tablet
Nhà Sản Xuất
-
Sản phẩm biệt dược : Briem
-
Công ty :
Novartis (Belgium, Philippines, Switzerland, Turkey), Meda (Denmark, Germany, Greece, Ireland, Italy, Netherlands, Spain)
Sản phẩm biệt dược : Cibacen
-
Sản phẩm biệt dược : Cibacene
-
Sản phẩm biệt dược : Lotensin
Tài Liệu Tham Khảo Thêm
National Drug Code Directory